MBCC: Will NGS change the way we treat metastatic breast cancer?
Following on from yesterday’s update on how proteomics and genomics can help us make better decisions in breast cancer at the Miami Breast Cancer Conference (#MBCC14) organised by PER, today also looks at the complexity of genomics, but from a different lens – can genomics impact the way we actually treat patients?
Interestingly, last week there was a rumour (unconfirmed) that Dr Debu Tripathy (UCLA) was heading to MD Anderson to head up the breast cancer division following Gabriel Hortobaygi’s retirement. That move was confirmed yesterday, with a tweet from Dr Naoto Ueno, who is part of the group:
It is our great pleasure to make an announcement that our new chair of Breast Medical Oncology will be Dr. Debashish (Debu) Tripathy !!
— Naoto Ueno, MD, PhD (@teamoncology) March 12, 2014
His talk on the increasing role of genomics in breast cancer on Friday was engaging, thoughtful and well delivered.
It also made me (and several others) stop and think.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
